Tobacco.org

Smoking cessation significantly increases adiponectin levels 

MedWire News: Researchers in Greece have discovered that smoking cessation, aided by the pharmacologic agent buproprion, results in a significant increase in adiponectin levels within 2 months.

“Smoking has been associated with low serum levels of adiponectin, an adipocytokine with insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties,” say Stamatis Efstathiou (Hygeias Melathron, Athens) and colleagues.

“However, no data are available so far in regard to the short-term impact of smoking cessation on serum adiponectin concentration.”

To investigate further, the team recruited 106 apparently healthy Greek smokers without additional cardiovascular risk factors to the study. The participants were prescribed the well-established pharmaceutical aid buproprion 150 mg/twice daily for a period of 9 weeks. . . .

Presenting their results at a poster session at the European Society of Cardiology annual meeting in Barcelona, Spain, the researchers report that quitters’ adiponectin levels were significantly increased by 1.9 µg/ml compared with baseline by the end of the study.

In contrast, non-quitters’ adiponectin levels remained unchanged at 9 weeks.

Jump to full article »